US 12,007,394 B2
Biomarker for prognosis of thyroid cancer
Chih-Yuan Wang, Taipei (TW); Tien-Chun Chang, Taipei (TW); and Pei-Jie Huang, Taipei (TW)
Assigned to NATIONAL TAIWAN UNIVERSITY, Taipei (TW)
Appl. No. 16/638,157
Filed by Chih-Yuan Wang, Taipei (TW)
PCT Filed May 15, 2018, PCT No. PCT/IB2018/053374
§ 371(c)(1), (2) Date Feb. 11, 2020,
PCT Pub. No. WO2019/053521, PCT Pub. Date Mar. 21, 2019.
Claims priority of provisional application 62/650,171, filed on Sep. 18, 2017.
Prior Publication US 2021/0373025 A1, Dec. 2, 2021
Int. Cl. G01N 33/574 (2006.01)
CPC G01N 33/57488 (2013.01) [G01N 33/57407 (2013.01)] 11 Claims
 
1. A method of prognosis of thyroid cancer in a subject in need thereof, comprising:
obtaining an exosome from the subject who had received a therapy of thyroid cancer, wherein the exosome is isolated from urine;
detecting a trend of a level of thyroglobulin present in the exosome;
diagnosing the subject with recurrent thyroid cancer for prognosis when the presence of thyroglobulin in the exosome shows an increasing trend,
wherein the increasing trend is that within six months after the therapy of thyroid cancer, a serum thyroglobulin of the diagnosed subject is undetectable, while the urinary exosomal thyroglobulin of the diagnosed subject is detected at a level of 0.412 ng/mL to 9.29 ng/ml; and
administering a thyroid cancer treatment to the diagnosed subject.